Table 1.
Patients characteristics at baseline and end of treatment
| Characteristics | Baseline | End of treatment | p |
|---|---|---|---|
| Number of patients | 769 | ||
| Age (years) | 64 (18–88) | ||
| Gender, male | 317 (41.2) | ||
| Genotype, 1/2 | 539/230 | ||
| Liver cirrhosis | 149 (19.4) | ||
| Diabetes | 93 (12.1) | ||
| BMI (kg/m2) | 22.9 (14.4–38.8) | ||
| eGFR (ml/min/1.73 m2) | 73.6 (30.4–187.8) | ||
| Treatment | |||
| daclatasvir + asunaprevir | 258 (33.6) | ||
| sofosbuvir/ledipasvir | 93 (12.1) | ||
| ombitasvir/paritaprevir/ritonavir | 53 (6.9) | ||
| elbasvir + grazoprevir | 71 (9.2) | ||
| daclatasvir/asunaprevir/beclabuvir | 18 (2.3) | ||
| glecaprevir/pibrentasvir | 84 (10.9) | ||
| sofosbuvir + ribavirin | 188 (24.4) | ||
| ombitasvir/paritaprevir/ritonavir + ribavirin | 4 (0.5) | ||
| Platelets count (×104/µl) | 15.7 (3.8–22.0) | 16.1 (3.8–43.4) | <0.001 |
| AST (U/L) | 39 (11–272) | 24 (10–99) | <0.001 |
| ALT (U/L) | 39 (7–255) | 17 (4–106) | <0.001 |
| Total bilirubin (mg/dl) | 0.7 (0.2–2.3) | 0.7 (0.1–3.0) | 0.476 |
| Albumin (g/dl) | 4.1 (2.0–5.1) | 4.2 (2.7–5.3) | <0.001 |
| M2BPGi | 2.0 (0.1–24.2) | 1.1 (0.2–11.8) | <0.001 |
| AFP (ng/ml) | 4.2 (1.0–634.9) | 3.1 (0.9–27.1) | <0.001 |
| Serum zinc (µg/dl) | 69 (28–116) | 68 (42–142) | 0.122 |
Categorical variables expressed as number (%) and the continuous variables as median (range). AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; M2BPGi, Mac-2 binding protein glycosylation isomer.